[1] GO R S,ADIEI A A.Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin[J].Ann Oncol,1999,17(1):13-21.
[2] SCHMITTGEN T D,LIVAK K J.Analyzing real-time PCR data by the comparative CT method[J].Nature Protocols,2008,3:1101-1108.
[3] JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[4] KODAMA J,SEKI N,HIRAMATSU Y.Chemotherapy for high-risk early-stage endometrial cancer[J].Curr Opin Obstet Gynecol,2007,19(1):42-47.
[5] PECTASIDES D,XIROS N,PAPAXOINIS G,et al.Carboplatin and paclitaxel in advanced or metastatic endometrial cancer[J]. Gynecol Oncol,2008,109(2):250-254.
[6] ITO K,TSUBAMOTO H,ITANI Y,et al.A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer:A Kansai Clinical Oncology Group study (KCOG0015 trial)[J].Gynecol Oncol,2011,120:193-197.
[7] CAREY M S,GAWLIK C,FUNG-KEE-FUNG M,et al.Systematic review of systemic therapy for advanced or recurrent endometrial cancer[J].Gynecol Oncol,2006,101(1):158-167.
[8] 王鹰,李苏宜.抗肿瘤血管生成分子靶向治疗临床研究进展[J].东南大学学报:医学版,2007,26(6):476-480.
[9] HUANG H,BHAT A,WOODNUTT G,et al.Targeting the ANGPT-TIE2 pathway in malignancy[J].Nat Rev Cancer,2010,10:575-585.
[10] MAI J,SONG S,RUI M,et al.A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells[J].J Control Release,2009,139:174-181.
[11] YAMAKAWA D,KIDOYA H,SAKIMOTO S,et al.2-Methoxycinnamaldehyde inhibits tumor angiogenesis by suppressing Tie2 activation[J].Biochem Biophys Res Commun,2011,415(1):174-180. |